Bob Dole pushes MIRA
This article was originally published in The Gray Sheet
Executive Summary
Former Kansas senator is helping to publicize the "Medicare Innovation Responsiveness Act." Dole, who was implanted with an endograft to treat an abdominal aortic aneurysm, appeared at a recent press event introducing the bill. HR 941, sponsored by Reps. Jim Ramstad (R-Minn.) and Anna Eshoo (D-Calif.), would establish a CMS Council for Technology & Innovation and extend Medicare coverage to IDE trials (1"The Gray Sheet" March 3, 2003, p. 8)...
You may also be interested in...
MIRA Bill Calls For One-Year Ceiling On National Coverage Decisions
Pending Medicare coverage requests for positron emission tomography (PET) additional indications will need to be resolved rapidly if the "Medicare Innovation Responsiveness Act of 2003" is signed into law
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.